New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareChonluten vs CJC-1295

Chonluten vs CJC-1295

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Chonluten
Growth Hormone Peptides
CJC-1295
Summary
Chonluten is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific to the bronchi and lungs. While related to Bronchogen (a tetrapeptide), Chonluten is a shorter tripeptide sequence. It supports bronchial mucosal cell function, promotes respiratory epithelial regeneration, and is used in protocols for COPD, chronic bronchitis, and pulmonary anti-aging.
CJC-1295 is a synthetic GHRH analog that stimulates the pituitary gland to produce and release growth hormone. The DAC (Drug Affinity Complex) version has a markedly extended half-life. The No DAC version (Modified GRF 1-29) preserves natural pulsatile GH release and is preferred in most protocols.
Half-Life
Short (minutes for the peptide); sustained gene-regulatory effects
~30 minutes (No DAC) / 6–8 days (with DAC)
Admin Route
SubQ, Oral
SubQ
Research
Typical Dose
10 mg per day
100 mcg
Frequency
Daily for 10–30 days
Once daily, before bed
Key Benefits
  • Supports bronchial mucosal regeneration and repair
  • May improve mucociliary clearance in chronic respiratory conditions
  • Anti-inflammatory effects on bronchial epithelium
  • Pulmonary anti-aging and tissue preservation
  • Supports lung function in COPD and chronic bronchitis
  • Well tolerated in combination with other Khavinson bioregulators
  • Short tripeptide with efficient cellular penetration
  • Sustained increase in growth hormone levels
  • Enhanced muscle growth and strength
  • Improved fat metabolism and body composition
  • Better recovery and tissue repair
  • Increased bone density
  • Enhanced immune function
  • Improved skin quality and collagen production
  • Synergistic GH release when combined with GHRPs like Ipamorelin
Side Effects
  • Generally well tolerated
  • Mild injection site reactions possible
  • No significant adverse pulmonary events reported
  • Water retention / puffiness
  • Carpal tunnel syndrome (with prolonged use)
  • Injection site irritation
  • Hunger increase (minor)
  • +1 more
Stacks With